Citius Oncology, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Citius Oncology, Inc. (CTOR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 5.75 million shares for the 12-month period ending 2025-09-30, per its 10-K filed 2025-12-23.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2025-12-23
- Citius Oncology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 0.00 shares.
- Citius Oncology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-06-30 was 0.00 shares.
- Citius Oncology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-03-31 was 0.00 shares.
- Citius Oncology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-12-31 was 5.75M shares.
- Citius Oncology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 5.75M shares, a 3733.33% increase from fiscal 2024.
- Citius Oncology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 150.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2025-09-30 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | 0.00 shares derived: sum of 2 quarters · filed 2025-12-23 | 0.00 shares derived: sum of 3 quarters · filed 2025-12-23 | 5.75M shares 10-K · filed 2025-12-23 |
| 2025-06-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-12 | 0.00 shares derived: sum of 2 quarters · filed 2025-08-12 | 5.75M shares 10-Q · filed 2025-08-12 | |
| 2025-03-31 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-14 | 5.75M shares 10-Q · filed 2025-05-14 | ||
| 2024-12-31 | 5.75M shares 10-Q · filed 2025-02-14 | |||
| 2024-09-30 | 150.00K shares 10-K · filed 2024-12-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |